IOR researchers suggest that androgen-deprivation treatments for prostate cancer could protect men from COVID-19

The so-called "androgen-deprivation" treatments used in prostate cancer therapy may have a protective effect against COVID-19. A study conducted by the Istitute of Oncology Research (IOR, affiliated to USI) based on health data obtained from the Veneto region in Italy has observed a lower risk of developing the coronavirus disease for men subject to this type of therapy. The study, performed in collaboration with the Institute for Research in Biomedicine (IRB, also affiliated to USI) and led by ...
More

Tiziano Bernasocchi awarded “PhD in Life Sciences” from the University of Lausanne

Tiziano Bernasocchi, molecular biologist in the Prostate Cancer Genome group of Prof. Jean-Philippe Theurillat, successfully defended his Ph.D. on April 21st, 2020, from the University of Lausanne. He presented the work entitled: Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer.  The research work elucidates an enigmatic finding of comprehensive prostate cancer genome studies, namely that recurrent genetic rearrangements of the ERG transcription factor neve...
More

Geniver El Tekle received the “PhD in Life Sciences” from the University of Lausanne

Geniver El Tekle successfully defended her Ph.D. thesis at the Institute of Oncology Research (IOR) in Bellinzona on April 20th, 2020. Her thesis entitled “ Functional Characterization and Therapeutic Implications of SPOP Mutations in Endometrial and Prostate Cancer” was carried out in the Functional Cancer Genomics group directed by Prof. Jean-Philippe Theurillat at the IOR.   The thesis focused on the role of missense mutations affecting the substrate-recognition domain of the ubiquitin lig...
More

IOR paves the way for the clinical development of a therapy against prostate cancer metastasis

An international group of researchers, led by Andrea Alimonti, Group Leader at the Institute of Oncology Research (IOR, affiliated to USI) and Professor at the USI Faculty of Biomedical Sciences and at ETH Zurich, has discovered a mechanism to recognise the cancer cells responsible for prostate cancer and selectively eliminate them. The study was published on April 6 by the Journal of Clinical Investigation (JCI).   Background Prostate cancer is one of the most frequent causes of m...
More

New Review on the International Journal of Molecular Sciences

The PI3K/AKT/mTOR pathway is one of the signaling cascades most commonly hijacked by cancer cells. Lymphoma cells are no exceptions. Thus, their pharmacological targeting is being extensively explored. Following their previous work with the dual PI3K/mTOR inhibitor bimiralisib (PQR309) (PMID: 29066507), Dr Chiara Tarantelli and Prof. Francesco Bertoni from IOR, together with PD Anastasios Stathis from the local Oncology Institute of Southern Switzerland, and Dr Antonio Lupia, previous visitin...
More

A new publication by Prof. Francesco Bertoni LAB

Antibody-drug conjugates (ADCs) are an effective therapeutic modality to deliver potent cytotoxic molecules to tumor cells bearing a specific antigen. Following their previous work on the anti-CD19 ADCs huB4-DGN462 and coltuximab ravtansine (SAR3419) (PMID 30733273), the research team led by Prof. Francesco Bertoni has now characterized the novel ADC MEN1309/OBT076 targeting CD205 for its anti- lymphoma activity. The work done by Dr Eugenio Gaudio, Dr Chiara Tarantelli and Colleagues, now pub...
More